The company said Monday it will deliver technical and support services to the NIH-funded HIV clinical trials network and its community advocates as well as implement ACTG's scientific research plan.
Under the subaward from the ACTG Leadership and Operations Center, DLH will also facilitate network consortium partner communications and collaboration, develop site capacity, and draft and apply protocols.
The company previously developed the Network Management Information System, a secure web-based platform, in support of ACTG's scientific, administrative and governance framework.
"DLH is honored to continue its longstanding support of ACTG in its mission to cure HIV and reduce the burden of other emerging infectious diseases," said Zach Parker, CEO and president at DLH.
ACTG performs epidemiology studies and has sites in 15 countries. The network also took steps to explore and validate potential COVID-19 treatments under the ACTIV-2 project.